Molecular Cancer Therapeutics
New Therapeutic Cancer Vaccine with Lenalidomide Induces Potent T-cell Immunity and Inhibits HPV E6/E7–Expressing Tumor Growth in Mice
Abstract Current prophylactic human papillomavirus (HPV) vaccines prevent infection but have limited therapeutic benefit in established HPV-driven malignancies. To address this unmet need, we developed VTX-067, a modular self-assembling therapeutic cancer vaccine consisting of a recombinant Mycobacterium tuberculosis heat shock protein 70–avidin fusion (MAV) noncovalently bound to biotinylated HPV E6/E7 MHC class I– and II–restricted peptide concatemers. MAV is produced in Chinese hamster ovary cells with minimal e …